JP2020530832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530832A5 JP2020530832A5 JP2019572820A JP2019572820A JP2020530832A5 JP 2020530832 A5 JP2020530832 A5 JP 2020530832A5 JP 2019572820 A JP2019572820 A JP 2019572820A JP 2019572820 A JP2019572820 A JP 2019572820A JP 2020530832 A5 JP2020530832 A5 JP 2020530832A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- weight
- pharmaceutical
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 40
- -1 4-chloro-2- (morpholin-4-yl) thiazole-5-yl Chemical group 0.000 claims 13
- 239000003085 diluting agent Substances 0.000 claims 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 7
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 7
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 6
- 229960001021 lactose monohydrate Drugs 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 5
- 229940127557 pharmaceutical product Drugs 0.000 claims 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000007909 solid dosage form Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 229940032147 starch Drugs 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- NQIWTFFSXXTCBM-UHFFFAOYSA-M [Br-].C(CCCCCCCCCCCCCCC)C[N+](C)(C)CCCCCCCCCCCCCC Chemical compound [Br-].C(CCCCCCCCCCCCCCC)C[N+](C)(C)CCCCCCCCCCCCCC NQIWTFFSXXTCBM-UHFFFAOYSA-M 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000008051 alkyl sulfates Chemical class 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 229960003563 calcium carbonate Drugs 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 229960001714 calcium phosphate Drugs 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 229920001592 potato starch Polymers 0.000 claims 1
- 239000000344 soap Chemical class 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 229940001593 sodium carbonate Drugs 0.000 claims 1
- 235000017550 sodium carbonate Nutrition 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023084119A JP7720354B2 (ja) | 2017-08-14 | 2023-05-22 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545393P | 2017-08-14 | 2017-08-14 | |
| US62/545,393 | 2017-08-14 | ||
| PCT/US2018/046707 WO2019036472A1 (en) | 2017-08-14 | 2018-08-14 | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023084119A Division JP7720354B2 (ja) | 2017-08-14 | 2023-05-22 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530832A JP2020530832A (ja) | 2020-10-29 |
| JP2020530832A5 true JP2020530832A5 (enExample) | 2021-09-24 |
| JP7285222B2 JP7285222B2 (ja) | 2023-06-01 |
Family
ID=65362465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572820A Active JP7285222B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2023084119A Active JP7720354B2 (ja) | 2017-08-14 | 2023-05-22 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023084119A Active JP7720354B2 (ja) | 2017-08-14 | 2023-05-22 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210137935A1 (enExample) |
| EP (1) | EP3630763A4 (enExample) |
| JP (2) | JP7285222B2 (enExample) |
| KR (1) | KR102644781B1 (enExample) |
| CN (1) | CN110997667A (enExample) |
| AR (1) | AR112471A1 (enExample) |
| AU (3) | AU2018318990B2 (enExample) |
| BR (1) | BR112020002966A2 (enExample) |
| CA (1) | CA3064445A1 (enExample) |
| EA (1) | EA202090321A1 (enExample) |
| MX (2) | MX2019015318A (enExample) |
| TW (2) | TWI803504B (enExample) |
| WO (1) | WO2019036472A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3096756T (pt) | 2014-01-21 | 2024-08-26 | Neurocrine Biosciences Inc | Antagonistas do recetor crf1 para o tratamento da hiperplasia adrenal congénita |
| BR112020002967A2 (pt) | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| AU2018318990B2 (en) * | 2017-08-14 | 2023-01-05 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| WO2019210266A1 (en) * | 2018-04-27 | 2019-10-31 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| MA54395A (fr) | 2018-12-07 | 2022-03-16 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale |
| EP3986416A4 (en) * | 2019-07-19 | 2023-06-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| WO2022036123A1 (en) | 2020-08-12 | 2022-02-17 | Spruce Biosciences, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123835A0 (en) | 1996-02-07 | 1998-10-30 | Janssen Pharmaceutica Nv | Pyrazolopyrimidines as CRF receptor antagonists |
| CN1137123C (zh) | 1998-01-28 | 2004-02-04 | 杜邦药品公司 | 吡咯并三嗪和嘧啶化合物 |
| IL137019A (en) * | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| KR100664479B1 (ko) * | 1999-12-08 | 2007-01-04 | 파마시아 코포레이션 | 발데콕시브 조성물 |
| EP1722826A2 (en) * | 2004-02-13 | 2006-11-22 | SB Pharmco Puerto Rico Inc. | Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses |
| US7612067B2 (en) | 2005-03-21 | 2009-11-03 | Eli Lilly And Company | Imidazopyridazine compounds |
| BRPI0717070A2 (pt) * | 2006-09-20 | 2013-09-24 | Lilly Co Eli | compostos de tiofeno pirazolopirimidina |
| HRP20100516T1 (hr) * | 2006-09-20 | 2010-10-31 | Eli Lilly And Company | Tiazolpirazolopirimidini kao antagonisti receptora crf1 |
| CA2739422C (en) * | 2008-10-02 | 2013-03-12 | Eli Lilly And Company | Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes |
| AU2018318990B2 (en) * | 2017-08-14 | 2023-01-05 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
-
2018
- 2018-08-14 AU AU2018318990A patent/AU2018318990B2/en active Active
- 2018-08-14 EP EP18846043.0A patent/EP3630763A4/en active Pending
- 2018-08-14 CA CA3064445A patent/CA3064445A1/en active Pending
- 2018-08-14 WO PCT/US2018/046707 patent/WO2019036472A1/en not_active Ceased
- 2018-08-14 US US16/639,540 patent/US20210137935A1/en not_active Abandoned
- 2018-08-14 BR BR112020002966-1A patent/BR112020002966A2/pt not_active Application Discontinuation
- 2018-08-14 KR KR1020207005534A patent/KR102644781B1/ko active Active
- 2018-08-14 TW TW107128345A patent/TWI803504B/zh active
- 2018-08-14 JP JP2019572820A patent/JP7285222B2/ja active Active
- 2018-08-14 EA EA202090321A patent/EA202090321A1/ru unknown
- 2018-08-14 CN CN201880038596.0A patent/CN110997667A/zh active Pending
- 2018-08-14 TW TW112117030A patent/TW202400179A/zh unknown
- 2018-08-14 MX MX2019015318A patent/MX2019015318A/es unknown
- 2018-08-14 AR ARP180102314 patent/AR112471A1/es unknown
-
2019
- 2019-12-16 MX MX2022015858A patent/MX2022015858A/es unknown
-
2023
- 2023-03-20 AU AU2023201703A patent/AU2023201703B2/en active Active
- 2023-05-22 JP JP2023084119A patent/JP7720354B2/ja active Active
-
2024
- 2024-12-16 AU AU2024278470A patent/AU2024278470A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530832A5 (enExample) | ||
| TWI583384B (zh) | 包含４－胺基－５－氟－３－［６－（４－甲基哌嗪－１－基）－１ｈ－苯并咪唑－２－基］－１ｈ－喹啉－２－酮乳酸鹽單水合物之醫藥組合物 | |
| ME01980B (me) | Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat | |
| US9402907B2 (en) | Pharmaceutical composition containing diamine derivative | |
| US9629808B2 (en) | Sustained-release solid preparation for oral use | |
| JP2023116489A5 (enExample) | ||
| FI3999038T3 (fi) | Sydämen sarkomeerin inhibiittorin oraalisia formulaatioita | |
| JP2016531151A5 (enExample) | ||
| RU2018129775A (ru) | Фармацевтическая композиция, включающая ингибитор янус-киназы или его фармацевтически приемлемую соль | |
| US20230390293A1 (en) | Pharmaceutical compositions of ibrutinib | |
| JP2007509891A5 (enExample) | ||
| JP2019526591A5 (enExample) | ||
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| WO2014060561A1 (en) | Oral pharmaceutical formulations comprising dabigatran | |
| AU2016231883B2 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| WO2010120963A1 (en) | Tablet formulation for p38 inhibitor and method | |
| WO2011080706A1 (en) | Enhanced solubility of ziprasidone | |
| BR112020002705A2 (pt) | composições extrudadas de enzalutamida | |
| JP2013528213A5 (enExample) | ||
| CZ2016538A3 (cs) | Farmaceutická kompozice obsahující dvě rozdílné účinné látky | |
| WO2015069203A1 (en) | Capsule comprising rupatadine fumarate and montelukast sodium | |
| WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
| JP2018184382A (ja) | エゼチミブ含有錠剤およびその製法 | |
| JP6824816B2 (ja) | 口腔内崩壊性被覆錠剤及び口腔内崩壊性被覆錠剤の被覆層用組成物 | |
| WO2017037645A1 (en) | Stable pharmaceutical formulations of teriflunomide |